Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FILO-AML-01-MIVONU
2025-521322-14-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib and azacitidine in acute myeloid leukemia (AML), sponsored by French Innovative Leukemia Organization. Primary endpoint: Relapse-free survival at 24 months. Planned start Dec 2025; status: authorised.
02
Drugs
ivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-521322-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521322-14-00.